Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center, Prospective, Randomized, Open-Label, Sponsor-Blinded, Active-Control (Heparin) Clinical Investigation to Evaluate the Safety and Effectiveness of B-Lock™ as an Antimicrobial Catheter Lock Solution in Dialysis Patients With a Central Venous Catheter

NCT01989091 is registered in ClinicalTrials.gov with Great Lakes Pharmaceuticals Inc. as lead sponsor.

NCT NCT01989091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01989091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center, Prospective, Randomized, Open-Label, Sponsor-Blinded, Active-Control (Heparin) Clinical Investigation to Evaluate the Safety and Effectiveness of B-Lock™ as an Antimicrobial Catheter Lock Solution in Dialysis Patients With a Central Venous Catheter
Lead sponsor
Great Lakes Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2012
Completion date
October 31, 2014
Enrollment
270 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

dialysis catheter infections